Nyxoah to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Mont-Saint-Guibert, Belgium February 4, 2022, 10:30pm CET / 4:30pm ET Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(Nyxoah or the Company), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will be held virtually from February 15-17, 2022.
Olivier Taelman, Nyxoahs Chief Executive Officer, is scheduled to present a corporate update on Thursday, February 17, 2022, at 8:00am EST. This presentation will not be webcast due to the format of the conference. The Company will also be available for virtual 1x1 meetings with institutional investors registered for the event.
Nyxoahs updated Investor Presentation can be accessed on the Shareholder Information section of the Companys Investor Relations page.
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoahs lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the worlds most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Loic Moreau, Chief Financial Officer
+32 473 33 19 80
Jeremy Feffer, VP IR and Corporate Communications
+1 917 749 1494